Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
ScemblixⓇ launch off to a strong start
Sales evolution
USD m
Ex-US
US
31
25
52
10
444
41
42
37
25
29
25
Q1
Q2
Q3
Q4
2022
1. IQVIA: US Oct 2022 rolling three months 3L+ new patient start share.
33 Investor Relations | Q4 2022 Results
GROWTH
OSCEMBLIX®
(asciminib) 20 mg. 40 mg tablets
FY sales USD 149 million
US sales driven by patients resistant/intolerant to other
TKIs; CML 3L+ NBRx share at 29%1
Global rollout ongoing with approval in 40 countries;
access pathways in 9, negotiations ongoing in 30+
ASCEND IIT presented at ASH, showing promising
preliminary results and consistent tolerability in 1L CML
ASC4FIRST (1L registrational study) completed
enrollment ahead of plan, readout expected 2024
NOVARTIS | Reimagining MedicineView entire presentation